BRCA1 and neoplasm: Strengths include the multiethnic population-based sample with a high proportion of sTIL-enriched tumors, near-complete germline BRCA1/2 testing, a relatively young cohort (63% diagnosed at age <50 years, mean = 45.5) enriched for the aggressive tumor subtypes seen among younger women and reflective of the NC-BCFR sampling scheme (9), and nearly 20-year follow-up.